Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC(50)?

Development of drug resistance to imatinib mesylate in chronic myeloid leukemia (CML) patients is often accompanied by selection of point mutations in the kinase domain (KD) of the Bcr-Abl oncoprotein, where imatinib binds. Several second-generation tyrosine kinase inhibitors (TKIs) have been design...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Soverini, Simona, Rosti, Gianantonio, Iacobucci, Ilaria, Baccarani, Michele, Martinelli, Giovanni
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2011
Teme:
Leukemias
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228229/
https://ncbi.nlm.nih.gov/pubmed/21632458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0388
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki